Zhijie Wang

机构：Hubei University of Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Hubei University of Chinese Medicine, National Cancer Center, Zhejiang Province Institute of Architectural Design and Research, Peking University Cancer Hospital, Shandong Institute of Food and Drug Inspection, Zhejiang Cancer Hospital, Integrated Chinese Medicine (China), Hangzhou First People's Hospital · ORCID：0000-0002-7722-4956

发表论文 385 篇 · 总被引 9028 次 · h-index 46

代表论文

• Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study (2025 · Journal of Thoracic Oncology · 被引 16)
• The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist). (2025 · Journal of Clinical Oncology · 被引 11)
• Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients (2025 · Signal Transduction and Targeted Therapy · 被引 9)
• RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations (2025 · Cell Reports Medicine · 被引 6)
• Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study (2025 · The Innovation · 被引 5)
• Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study (2025 · Chinese Medical Journal - Pulmonary and Critical Care Medicine · 被引 2)